文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

氯胺酮作为酒精依赖药物治疗的概念验证研究:随机对照试验研究方案

A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2017-04-04

这是一项在英国两个中心开展的第二阶段随机双盲安慰剂对照平行组试验,计划纳入96例近期戒酒且伴抑郁症状的酒精依赖患者,比较三次氯胺酮(0.8 mg/kg,40分钟内静脉给药)或安慰剂(50 ml 0.9%氯化钠注射液,40分钟内静脉给药)联合七次手册化心理治疗或酒精教育对照的疗效。主要终点为6个月时复发率和6个月时戒酒天数百分比,次要终点包括3个月和6个月时戒酒天数百分比、耐受性(以脱落为指标)、不良事件、抑郁症状、渴求和生活质量。

要点

  • 96例近期戒酒且伴抑郁症状的酒精依赖患者随机分配至四组:氯胺酮或安慰剂联合心理治疗或酒精教育对照。
  • 氯胺酮剂量为0.8 mg/kg,40分钟内静脉给药,共三次;安慰剂为50 ml 0.9%氯化钠注射液,40分钟内静脉给药。
  • 主要终点为6个月时复发率和6个月时戒酒天数百分比。

核心结论

  • 该概念验证试验旨在初步评估重复氯胺酮联合心理治疗方案在严重酒精使用障碍患者中减少复发的有效性。

研究设计与样本

  • 第二阶段随机双盲安慰剂对照平行组临床试验,在英国英格兰西南部和伦敦两个中心开展,计划纳入96例近期戒酒且伴抑郁症状的酒精依赖患者。
  • 患者随机分配至四组:三次氯胺酮(0.8 mg/kg,40分钟内静脉给药)或安慰剂(50 ml 0.9%氯化钠注射液,40分钟内静脉给药),联合七次手册化心理治疗或酒精教育对照。
  • 在3个月和6个月时评估一系列心理和生物学变量。

主要发现

  • 主要终点为6个月时复发率和6个月时戒酒天数百分比。
  • 次要终点包括3个月和6个月时戒酒天数百分比、耐受性(以脱落为指标)、不良事件、抑郁症状、渴求和生活质量。

关键数值与推荐

  • 氯胺酮剂量为0.8 mg/kg,40分钟内静脉给药,共三次。
  • 安慰剂为50 ml 0.9%氯化钠注射液,40分钟内静脉给药。
  • 心理治疗为七次手册化心理治疗,对照为酒精教育。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme may be effective in reducing relapse in severe alcohol use disorder. This non-commercial proof-of-concept trial is aimed at making a preliminary assessment of the effectiveness of this combined treatment in this patient group. METHODS/DESIGN: This is a phase II, randomised, double-blind, placebo-controlled, parallel-group clinical trial taking place in two sites in the UK: the South West of England and London. Ninety-six recently detoxified alcoholics, with comorbid depressive symptoms, will be randomised to one of four treatment arms. Patients will receive either three sessions of ketamine (0.8 mg/kg administered intravenously (IV) over 40 minutes) or placebo (50 ml saline 0.9% IV over 40 minutes) plus either seven sessions of manualised psychological therapy or an alcohol education control. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. The primary endpoints are (1) relapse rates at 6 months and (2) percentage days abstinent at 6 months. Secondary endpoints include 3 and 6 month percentage days abstinence, tolerability (indicated by dropout), adverse events, depressive symptoms, craving and quality of life. DISCUSSION: This study will provide important information on a new combined psychological and pharmacological intervention aimed at reducing relapse rates in alcoholics. The findings would have broad application given the worldwide prevalence of alcoholism and its associated medical, psychological and social problems. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02649231 . Registered on 5 January 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. McAndrew A, Lawn W, Stevens T, et al. A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials. 2017. PMID: 28372596. doi:10.1186/s13063-017-1895-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。